What Genzyme Transgenics found in TSI

Genzyme Transgenics Corp. is following in its parent's footsteps, bringing in an operating company with revenues to support its long-term therapeutic product R&D.

GZTC purchased TSI Corp. in a stock transaction worth about $30 million. TSIN (Milford, Mass.) had $11 million in revenues for the quarter ended March 27, and reported a loss of $255,000 (1 cent per share).